AwardedPOLGoods
Dostawa produktu leczniczego zawierającego substancję czynną Mirvetuximabum soravtansinum referundowanego w ramach programu lekowego B.50. Leczenie chorych na raka jajnika, raka jajowodu lub raka otrzewnej.
- Published
- Published 27 October 2025
Overview
Dostawa produktu leczniczego zawierającego substancję czynną Mirvetuximabum soravtansinum referundowanego w ramach programu lekowego B.50. Leczenie chorych na raka jajnika, raka jajowodu lub raka otrzewnej.
Key details
- Country
- POL
- Status
- Awarded
- Category
- Goods
- Procedure
- Direct
- Published
- 27 October 2025
Pharmaceutical products
Award outcome
- Awarded value
- PLN 1,814,399
- Award date
- 17 October 2025
- Contract period
- — → 12 October 2026
- Abbvie Sp. z o.o.
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
27 October 2025
Contracting authority
Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie
Procuring entityLublin, POL
Authority website ↗
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.